《血管内皮细胞生长因子受体及其抑制剂的肿瘤治疗研究》由会员分享，可在线阅读，更多相关《血管内皮细胞生长因子受体及其抑制剂的肿瘤治疗研究（3页珍藏版）》请在金锄头文库上搜索。
1、5=%3y0s8#4?王英娟, 赵玲娣,司玉玲(?gD?AS,?300140)ms|: R73 DSM:A cI|: 1006-2084( 2007) 20-1566-03K1:新生血管为肿瘤组织提供氧和营养物质, 在肿瘤的生长与转移过程中起重要作用b肿瘤血管的形成是多种细胞因子综合作用的结果,在这些细胞因子中研究最多的是血管内皮细胞生长因子b血管内皮细胞生长因子与其受体结合后通过酪氨酸激酶途径引起细胞的增殖及新生血管形成b抑制血管内皮细胞生长因子介导的途径可使肿瘤缩小,目前抗血管内皮细胞生长因子治疗已成为靶向治疗的热点b1oM:血管生成;血管内皮生长因子;血管内皮生长因子受体Study of
2、 VEGFR and its Inhibitors in the Treatment of Tumors WANG Ying-juan, ZHAO Ling-di, SIYu-ling. (Department of Tumor andHemotology, Forth CentralHospital of Tianjin, Tianjin 300140, China)Abstract:Thenew vascular provides oxygen and nutrients for thetumors and plays an important role in itsgrowth and
3、metastasis.The formation of vascular in tumors is theresult of interactions of many cytokines, amongwhich vascular epithelial growth factor is the onestudted most.Vascular epithelial growth factor binding with itsreceptor leads to cell proliferation and new vascular formation by tyrosine kinase path
4、way. The inhibition of thispathway may result in the shrinkage of tumor. At present, ant-i VEGFR therapy is becoming the hot spot of itstargeted therapy.Key words: Angiogenesis; Vascular endothelial growth factor; Vascular endothelial growth factor receptor?3M735,T5?%4!,?%yC!7b?53y03y0MTT,5=%3y0(vas
5、cular endothelial growth fac-tor,VEGF)Key0,?3MV?1T,C5=%3y0s8(vascular en-dothelial growth factor receptor, VEGFR)#4ZTB8b1 VEGF#VEGFR538FXi5533%55dV,?3M$ 1bT354!,?BV2 3mmb35?4!,7O4?%YV5d_)Mob353Vs53y053y0eb-VEGF#VEGFR?35V,TKa+sK1oey0,yN,EVEGF?VEGFRF?53F?,+M 2bVEGFB?vO?33r%y0,l3y0EBB,Ms034 103 45 103,
6、353Va 3,VEGF|1T2bhf/VCVEGFsVr,%h,VOVr,YV=%sT,35,F;?F,?%a?%gv%?sVEGF,sTO?5=%,=%9%M,5,?3,i45Yi,F8,%a8%=%,?%35,?Mb53h53,B53y0F53y0MT/bt?3y0,VEGF-A5=%3351,OM13V1T3bVEGFRt=%s8,8uatu=ubVEGFRVEGFPs8=8,s8?3M,=u,Ps81&,HP,YV/|0P=%9sb?(iVEGF-A mRNAVr,iOM1bYV+sVEGF-A?V?5,V7?4b2 FVEGF02.1 FVEGFF8 XZdl%kVEGFXHF8b
7、ecavizumab(FFVEGF-AXHF8)WbSZv5,?CBM1,FbecavizumabV453i 4bdl%ka5B(,?5s)l4(7.5mgPkg)v4(15mgPkg)becavizumabTY?C,v4becavizumabFrq31.4%,Z7.4,3i17.9,7vFrq18.8%,Z4.2,3i12. 3 5bSandler 6bevacizumab,?5sBdl%k5kV,k850,25%AUhfz, bevacizumabF3iqa3i#ZS(vFb2.2 EVEGFPVEGFRZ ?%,?M19VEGF-A5s0bY?5d,P91aM5dbF54YXi5d,yNV5C?q;6BZ,F5r?Qq1,7F53rV?5#1566#D82007M101320 Medical Recapitulate, October 2007,Vol. 13, No. 20?QHWb7,F53HAm)B(5ai?) ,MSbVEGFls04?Z,-tls045bXVEGF9B5Yiy0,?i?31 7bVEGFs0Ms8,35C3,5i,7OVT8,s8,=
